CureVac Sample Clauses

CureVac. Subject to CureVac's obligations as set forth in paras (ii) and (iii) of the Disclosure Letter, CureVac shall work exclusively with GSK on the Development, Manufacture and Commercialization of mRNA-Based vaccine and mRNA-Based antibody products targeting the SARS-CoV-2 Pathogen, and CureVac shall not, and shall procure that its Affiliates will not, develop, manufacture or commercialize, solely or with a Third Party, any mRNA-Based vaccine or mRNA-Based antibody targeting the SARS-CoV-2 Pathogen other than: (i) a COVID Product Developed and/or Commercialized under this Agreement, and (ii) the First-Gen COVID Vaccine Products, subject to Section 3.3.7. This Section 2.3.2 and the covenants set forth herein shall not apply to activities of any Third Party (or such Third Party's Affiliates) that becomes an Affiliate of CureVac solely as a result of a Change of Control in CureVac, provided that such activities are performed without using the CureVac mRNA technology described in the CureVac Know-How or within the scope of specification of the CureVac Patent Rights.
Sample 1See All (4)
AutoNDA by SimpleDocs
CureVac. Subject to CureVac's obligations as set forth in items (ii) and (iii) of the Disclosure Letter, CureVac shall work exclusively with GSK on the Development, Manufacture and Commercialization of Products targeting a Collaboration Pathogens, and CureVac shall not, and shall procure that its Affiliates will not, develop, manufacture or commercialize, solely or with a Third Party, any prophylactic and/or therapeutic mRNA-Based vaccine or mRNA-Based antibody targeting a Collaboration Pathogen other than a Product Developed and/or Commercialized under this Agreement. This Section 2.3.2 and the covenants set forth herein shall not apply to activities of any Third Party (or such Third Party's Affiliates) that becomes an Affiliate of CureVac solely as a result of a Change of Control in CureVac, provided that such activities are performed without using the CureVac mRNA technology described in the CureVac Know-How or within the scope of specification of the CureVac Patent Rights.
Sample 1Sample 2
CureVac. Overview: Founded in 2000 35, CureVac is a NASDAQ- listed36 biopharmaceutical company headquartered in Germany37. Its revenue in the same nine-month period increased by 304% from €10.6 million in 2019 to €42.8 million during the first nine months of 202038. Product specialisation: Messenger RNA (mRNA) technology (specifically its proprietary technology involving the use of non-chemically modified mRNA for prophylactic vaccines, cancer and antibody 25 European Pharmaceutical Review, “AstraZeneca”, xxxxx://xxx.xxxxxxxxxxxxxxxxxxxxxxxxxxxx.xxx/organisations/astrazeneca/ 26 AstraZeneca, “Contact Information”, xxxxx://xxx.xxxxxxxxxxx.xxx/investor-relations/annual-reports/annual-report-2016/contact-information.html 27 AstraZeneca, “FAQs”, xxxxx://xxx.xxxxxxxxxxx.xxx/investor-relations/faqs.html 28 AstraZeneca, “What science can do - AstraZeneca Annual Report and Form 20-F Information 2020”, xxxxx://xxx.xxxxxxxxxxx.xxx/content/dam/az/Investor_Relations/annual-report-2020/pdf/AstraZeneca_AR_2020.pdf 29 Xxxxx Xxxxxxxxx, “AstraZeneca COVID-19 Vaccine (AZD1222)”, January 27, 2021, xxxxx://xxx.xxx.xxx/vaccines/acip/meetings/downloads/slides-2021-01/02-COVID-Xxxxxxxxx.pdf 30 European Medicines Agency, “Vaxzevria (previously COVID-19 Vaccine AstraZeneca)”, xxxxx://xxx.xxx.xxxxxx.xx/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca 31 Reuters, “AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine”, June 13, 2020, xxxxx://xxx.xxxxxxx.xxx/article/us-health-coronavirus-vaccines-idUSKBN23K0HW 32 Xxxx Xxxxxxxxxxx, “The Serum Institute of India”, December 8, 2020, Fierce Pharma, xxxxx://xxx.xxxxxxxxxxxx.xxx/special-report/top-10-manufacturers-fight-against-covid-19-serum-institute-india 33 Xxxx Xxxxxxxxxxx, “AstraZeneca hopes warmer storage needs for COVID-19 vaccine will be an advantage against mRNA competitors”, November 23, 2020, Fierce Pharma, xxxxx://xxx.xxxxxxxxxxxx.xxx/manufacturing/astrazeneca-hopes-warmer-storage-needs-for-covid-19-vaccine-will-be-advantage-against 34 Xxxxxx Xxxxx, et al. Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology. medRxIV, 10 April 2021. Available online: xxxxx://xxx.xxx/10.1101/2021.04.08.21255103 35 CureVac, “History, How it all began”, xxxxx://xxx.xxxxxxx.xxx/en/about-us/historie-rework/ 36 Xxxxxx Xxxxxx, “XxxxXxx says well on track to request vaccine ...
Sample 1

Related to CureVac

  • Commercial Operation On or before December 31, 2023, Interconnection Customer must demonstrate commercial operation of all generating units. Demonstrating commercial operation includes achieving Initial Operation in accordance with Section 1.4 of Appendix 2 to this ISA and making commercial sales or use of energy, as well as, if applicable, obtaining capacity qualification in accordance with the requirements of the Reliability Assurance Agreement Among Load Serving Entities in the PJM Region.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act.

  • Elements Unsatisfactory Needs Improvement Proficient Exemplary IV-A-1. Reflective Practice Demonstrates limited reflection on practice and/or use of insights gained to improve practice. May reflect on the effectiveness of lessons/ units and interactions with students but not with colleagues and/or rarely uses insights to improve practice. Regularly reflects on the effectiveness of lessons, units, and interactions with students, both individually and with colleagues, and uses insights gained to improve practice and student learning. Regularly reflects on the effectiveness of lessons, units, and interactions with students, both individually and with colleagues; and uses and shares with colleagues, insights gained to improve practice and student learning. Is able to model this element.

  • Synchronization, Commissioning and Commercial Operation 4.1.1 The Power Producer shall give at least thirty (30) days written notice to the SLDC and GUVNL, of the date on which it intends to synchronize the Power Project to the Grid System.

  • Urgent Care This plan covers services received at an urgent care center. For other services, such as surgery or diagnostic tests, the amount that you pay is based on the type of service being provided. See Summary of Medical Benefits for details. Follow-up care (such as suture removal or wound care) should be obtained from your primary care provider or specialist.

  • Behavioral Health Services Behavioral health services include the evaluation, management, and treatment for a mental health or substance use disorder condition. For the purpose of this plan, substance use disorder does not include addiction to or abuse of tobacco and/or caffeine. Mental health or substance use disorders are those that are listed in the most updated volume of either: • the Diagnostic and Statistical Manual of Mental Disorders (DSM) published by the American Psychiatric Association; or • the International Classification of Disease Manual (ICD) published by the World Health Organization. This plan provides parity in benefits for behavioral healthcare services. Please see Section 10 for additional information regarding behavioral healthcare parity. Inpatient This plan covers behavioral health services if you are inpatient at a general or specialty hospital. See Inpatient Services in Section 3 for additional information. Residential Treatment Facility This plan covers services at behavioral health residential treatment facilities, which provide: • clinical treatment; • medication evaluation management; and • 24-hour on site availability of health professional staff, as required by licensing regulations. Intermediate Care Services This plan covers intermediate care services, which are facility-based programs that are: • more intensive than traditional outpatient services; • less intensive than 24-hour inpatient hospital or residential treatment facility services; and • used as a step down from a higher level of care; or • used a step-up from standard care level of care. Intermediate care services include the following: • Partial Hospital Program (PHP) – PHPs are structured and medically supervised day, evening, or nighttime treatment programs providing individualized treatment plans. A PHP typically runs for five hours a day, five days per week. • Intensive Outpatient Program (IOP) – An IOP provides substantial clinical support for patients who are either in transition from a higher level of care or at risk for admission to a higher level of care. An IOP typically runs for three hours per day, three days per week.

  • Commercial Copies The Corporation shall cause commercial copies of the Final Qualification Prospectus and any Supplementary Material to be delivered to the Agents without charge, in such numbers and in such cities in the Qualifying Jurisdictions as the Agents may reasonably request. Such delivery shall be effected as soon as practicable and, in any event, within two Business Days after the filing thereof in the Qualifying Jurisdictions.

  • Inspection/Testing All Products sold pursuant to this Agreement will be subject to inspection/testing by or at the direction of H- GAC and/or the ordering Customer, either at the delivery destination or the place of manufacture. In the event a Product fails to meet or exceed all requirements of this Agreement, and unless otherwise agreed in advance, the cost of any inspection and/or testing, will be the responsibility of the Contractor.

  • Repair Testing At the time of repair of a LIS trunk group, at no additional charge, tests will be performed to ensure that the service is operational and meets the applicable technical parameters.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

Time is Money Join Law Insider Premium to draft better contracts faster.